Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Researchers from Creatv Bio, Division of Creatv MicroTech, Inc. (Monmouth Junction, NJ) and The Mayo Clinic (Jacksonville, FL), in collaboration with BriaCell Therapeutics Corporation (Philadelphia, ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

In preclinical studies, anti-vascular endothelial growth factor (VEGF) and anti-PD-(L)1 antibodies were found to have synergistic antitumor activity. Anti-VEGF not only inhibits angiogenesis but ...

GEMSTONE-303 is the first trial demonstrating a statistically significant survival benefit for addition of an anti-PD-L1 antibody to standard chemotherapy for advanced gastric and gastroesophageal ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and ...

Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into ...